Skip to main content

Table 1 Baseline characteristics of patients included in QoL assessment

From: Quality of life and cost-effectiveness analysis of topical tranexamic acid and fibrin glue in femur fracture surgery

 

Control

N = 46

n (%)

FG

N = 46

n (%)

Topical TXA

N = 42

n (%)

p

Age (mean, SD)

84.06 (8.9)

81.74 (8.4)

83.57 (8.9)

0.412

Sex (women)

33 (71.7)

35 (76.1)

34 (81.0)

0.599

Medical background

Hypertension

28 (60.9)

25 (54.3)

25 (59.5)

0.838

Surgery

19 (41.3)

20 (43.5)

20 (47.6)

0.493

Diabetes

11 (23.9)

11 (23.9)

5 (11.9)

0.287

Chronic obstructive pulmonary disease

2 (4.3)

8 (17.4)

5 (11.9)

0.128

Chronic renal disease

6 (13.0)

4 (8.7)

3 (7.1)

0.647

Digestive ulcer

1 (2.2)

2 (4.3)

0

-

Haematological disease

0

2 (4.3)

0

-

Chronic liver disease

2 (4.3)

0

0

-

ASA

I

1 (2.2)

1 (2.2)

0

-

II

19 (41.3)

16 (34.8)

20 (47.6)

III

18 (39.1)

9 (19.6)

13 (30.9)

IV

1 (2.2)

2 (4.3)

0

Unknown

7 (15.2)

18 (39.1)

9 (21.5)

Surgery duration (Minutes, mean and SD)

77.9(24.33)

79.3 (23.53)

80.3 (20.3)

0.616

Prosthesis

Monopolar

24 (52.2)

19 (43.2)

15 (35.7)

0.289

Bipolar

20 (43.5)

19 (43.2)

22 (52.4)

Total

2 (4.3)

6 (13,6)

5 (11.9)

Type of prosthesis

Austin Moore®

24 (52.2)

23 (50.0)

17 (40.5)

0.638

HA Karey®

15 (32.6)

14 (30.4)

18 (42.9)

Other

7 (15.2)

9 (19.6)

7 (16.6)

 
  1. SD Standard Deviation, ASA Scale of surgical risk assessment of the American Society of Anaesthesiologists, TXA Tranexamic Acid, FG Fibrin Glue